Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas. more
Time Frame | BPTH | Sector | S&P500 |
---|---|---|---|
1-Week Return | 112.71% | -3.35% | -2.97% |
1-Month Return | 86.48% | -3.49% | -0.66% |
3-Month Return | 55.1% | -12.6% | 2.71% |
6-Month Return | -35.22% | -6.91% | 7.21% |
1-Year Return | -83.8% | 1.19% | 23.04% |
3-Year Return | -98.23% | -0.21% | 28.43% |
5-Year Return | -99.02% | 33.09% | 82.88% |
10-Year Return | -99.99% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 230.00K | 151.00K | 161.00K | 178.00K | 178.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.65,"profit":true},{"date":"2021-12-31","value":70,"profit":true},{"date":"2022-12-31","value":77.39,"profit":true},{"date":"2023-12-31","value":77.39,"profit":true}] |
Gross Profit | (230.00K) | (151.00K) | (161.00K) | (178.00K) | (178.00K) | [{"date":"2019-12-31","value":-23000000,"profit":false},{"date":"2020-12-31","value":-15100000,"profit":false},{"date":"2021-12-31","value":-16100000,"profit":false},{"date":"2022-12-31","value":-17800000,"profit":false},{"date":"2023-12-31","value":-17800000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 8.69M | 10.91M | 10.44M | 13.90M | 15.84M | [{"date":"2019-12-31","value":54.87,"profit":true},{"date":"2020-12-31","value":68.85,"profit":true},{"date":"2021-12-31","value":65.92,"profit":true},{"date":"2022-12-31","value":87.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (8.69M) | (10.91M) | (10.44M) | (13.90M) | (15.84M) | [{"date":"2019-12-31","value":-869300000,"profit":false},{"date":"2020-12-31","value":-1090800000,"profit":false},{"date":"2021-12-31","value":-1044300000,"profit":false},{"date":"2022-12-31","value":-1390100000,"profit":false},{"date":"2023-12-31","value":-1584300000,"profit":false}] |
Total Non-Operating Income/Expense | 188.00K | 52.00K | 6.00K | 66.00K | (183.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":27.66,"profit":true},{"date":"2021-12-31","value":3.19,"profit":true},{"date":"2022-12-31","value":35.11,"profit":true},{"date":"2023-12-31","value":-97.34,"profit":false}] |
Pre-Tax Income | (8.60M) | (10.88M) | (10.44M) | (13.87M) | (16.08M) | [{"date":"2019-12-31","value":-859900000,"profit":false},{"date":"2020-12-31","value":-1088200000,"profit":false},{"date":"2021-12-31","value":-1044000000,"profit":false},{"date":"2022-12-31","value":-1386800000,"profit":false},{"date":"2023-12-31","value":-1607800000,"profit":false}] |
Income Taxes | (94.00K) | (26.00K) | (3.00K) | (33.00K) | - | [{"date":"2019-12-31","value":-9400000,"profit":false},{"date":"2020-12-31","value":-2600000,"profit":false},{"date":"2021-12-31","value":-300000,"profit":false},{"date":"2022-12-31","value":-3300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (8.51M) | (10.86M) | (10.44M) | (13.84M) | - | [{"date":"2019-12-31","value":-850500000,"profit":false},{"date":"2020-12-31","value":-1085600000,"profit":false},{"date":"2021-12-31","value":-1043700000,"profit":false},{"date":"2022-12-31","value":-1383500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (8.60M) | (10.88M) | (10.44M) | (13.87M) | (16.67M) | [{"date":"2019-12-31","value":-859900000,"profit":false},{"date":"2020-12-31","value":-1088200000,"profit":false},{"date":"2021-12-31","value":-1044000000,"profit":false},{"date":"2022-12-31","value":-1386800000,"profit":false},{"date":"2023-12-31","value":-1667200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (8.51M) | (10.86M) | (10.44M) | (13.84M) | (16.08M) | [{"date":"2019-12-31","value":-850500000,"profit":false},{"date":"2020-12-31","value":-1085600000,"profit":false},{"date":"2021-12-31","value":-1043700000,"profit":false},{"date":"2022-12-31","value":-1383500000,"profit":false},{"date":"2023-12-31","value":-1607800000,"profit":false}] |
EPS (Diluted) | (3.27) | (2.82) | (1.57) | (1.90) | (8.56) | [{"date":"2019-12-31","value":-327,"profit":false},{"date":"2020-12-31","value":-282,"profit":false},{"date":"2021-12-31","value":-157,"profit":false},{"date":"2022-12-31","value":-190,"profit":false},{"date":"2023-12-31","value":-856,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BPTH | |
---|---|
Cash Ratio | 0.17 |
Current Ratio | 0.86 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BPTH | |
---|---|
ROA (LTM) | -140.03% |
ROE (LTM) | -366.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BPTH | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.24 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.24 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BPTH | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.33 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.03 |
PEG | NM |
Bio Path Holdings Inc (BPTH) share price today is $1.49
Yes, Indians can buy shares of Bio Path Holdings Inc (BPTH) on Vested. To buy Bio Path Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BPTH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bio Path Holdings Inc (BPTH) via the Vested app. You can start investing in Bio Path Holdings Inc (BPTH) with a minimum investment of $1.
You can invest in shares of Bio Path Holdings Inc (BPTH) via Vested in three simple steps:
The 52-week high price of Bio Path Holdings Inc (BPTH) is $12. The 52-week low price of Bio Path Holdings Inc (BPTH) is $0.59.
The price-to-earnings (P/E) ratio of Bio Path Holdings Inc (BPTH) is
The price-to-book (P/B) ratio of Bio Path Holdings Inc (BPTH) is 2.33
The dividend yield of Bio Path Holdings Inc (BPTH) is 0.00%
The market capitalization of Bio Path Holdings Inc (BPTH) is $2.88M
The stock symbol (or ticker) of Bio Path Holdings Inc is BPTH